Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Diabetic kidney disease (DKD) significantly elevates cardiovascular disease (CVD) risk.
• Traditional risk factors like diabetes mellitus (DM), hypertension, and obesity only partially explain this increased risk.
• Identifying novel risk factors is crucial for DKD-CVD risk stratification and treatment development.

Purpose of the Study:

• To review current knowledge on emerging cardiovascular risk markers in DKD patients.
• To highlight biomarkers that consistently predict cardiovascular events in this population.
• To inform potential integration of novel markers into clinical practice for improved patient management.

Main Methods:

• Literature review of studies investigating novel cardiovascular risk markers in DKD.
• Analysis of biomarker data related to cardiovascular event prediction in DKD cohorts.
• Synthesis of evidence on the clinical utility of emerging biomarkers.

Main Results:

• Fibroblast growth factor-23 (FGF-23) and copeptin are extensively studied and consistently predict cardiovascular events in DKD.
• These biomarkers offer additional predictive value beyond traditional risk factors.
• Evidence suggests their potential role in identifying high-risk DKD individuals.

Conclusions:

• Emerging biomarkers, particularly FGF-23 and copeptin, are valuable in assessing cardiovascular risk in DKD.
• Incorporating these markers into risk stratification strategies may improve patient outcomes.
• Further research can validate their role in guiding aggressive cardiovascular risk management in DKD.